[1] Fletcher JA, Kosakewich HP, Hoffer FA, Lage JM, Weidner N, Tepper R, Pinkus GS, Morton CC, Corson JM. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med 324:436-442, 1991. 

[2] Fletcher JA, Morton CC, Pavelka K, Lage JM. Chromosome aberrations in uterine smooth muscle tumors: Potential diagnostic relevance of cytogenetic instability. Cancer Res 50:4092-4097, 1990. 

[3] Sreekantaiah C, Davis JR, Sandberg AA. Chromosomal abnormalities in leiomyosarcomas Am J Pathol 142:293-305, 1993. 

[4] Nilbert M, Heim S, Mandahl N, Floderus UM, Willen H, Akerman M, Mitelman F. Ring formation and structural rearrangements of chromosome 1 as secondary changes in uterine leiomyomas with t(12;14)(q14-15;q23-24). Cancer Genet Cytogenet 36:183-190, 1988. 

[5] Maelandsmo GM, Berner J-M, Florenos JA, Forus A, Hovig E, Fodstad O, Myklebust O. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and MRNA levels of CDK4 and CCND1. Br J Cancer 72:393-398, 1995. 

[6] Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778, 1995. 

[7] Khatib ZA, Matsushime H, Valentine M, Shapiro DN , Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 53:5535-5541,1993. 

[8] Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, Fletcher CDM, Knight JC, Fung Y-K, Reeves BR, Cooper CS. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 60:202-205,1989. 

[9] Florenes VA, Moelandsmo GM, Fours A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcription levels in human sarcomas: Relationship to TP53 gene status. J Natl Cancer Inst 87:1297-1302, 1994. 

[10] Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CDM, Ball A, Thomas M, Gusterson BA, Cooper CS. Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RB1 gene. Oncogene 5:1297-1301, 1990. 

[11] Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863-5867, 1990. 

[12] Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 52:2231-2234, 1993. 

[13] Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline M. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86:6783-6787, 1989. 

[14] Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719, 1987. 

[15] Gill S, Stratton MR, Patterson H, Spurr NK, Fisher C, Gusterson B, Cooper CS. Detection of transforming genes by transfection of DNA from primary soft tissue tumours. Oncogene 6: 1651-1656, 1991. 

[16] Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, Thomas M, Grimer R, Gusterson BA, Cooper CS. Abnormalities of the p53, MDM2 and DCC genes in human leiomyosarcomas. Oncogene 69:1052-1058, 1994. 